Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine

12 May 2015

Abstract excerpt

Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of childhood epilepsy syndromes. Distinct de novo mutations in the SCN1A gene are responsible for over 80% of DS cases. While DS is largely resistant to treatment with existing anti-epileptic drugs, promising results have been obtained in clinical trials with human patients treated with the serotonin agonist fenfluramine as an add-on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsy research and treatment
Share to Zebrafish Biomedical Research Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25965391
DOI: 10.1371/journal.pone.0125898

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluraminePMID 25965391Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read ↗

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model.Semantic proximity Read ↗

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndromeSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet SyndromeSemantic proximity Read ↗

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read ↗

SCN1A as a therapeutic target for Dravet syndrome.Semantic proximity Read ↗

Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafishSemantic proximity Read ↗

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.Semantic proximity Read ↗

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.Semantic proximity Read ↗

Building a zebrafish toolkit for investigating the pathobiology of epilepsy and identifying new treatments for epileptic seizures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.